Form 4: National Healthcare Corp. Senior VP & General Counsel, Josh A. McCreary, Reports Acquisition of Restricted Stock and Stock Options
SEC Form 4 Filing
Josh A. McCreary, Senior VP & General Counsel of National Healthcare Corp, reports the acquisition of 1,385 shares of restricted stock and stock options.
Summary
- On March 5, 2025, Josh A. McCreary, Senior VP & General Counsel of National Healthcare Corp (NHC), reported transactions involving NHC's common stock.
- McCreary acquired 1,385 shares of common stock through a grant of restricted shares.
- These restricted shares are subject to a three-year vesting schedule, with 33 1/3% vesting on January 1, 2026, another 33 1/3% vesting on January 1, 2027, and the final 33 1/3% vesting on January 1, 2028.
- McCreary also acquired options to purchase 12,000 shares of common stock with an exercise price of $94.10, exercisable from March 5, 2025, and expiring on March 5, 2029.
- Following these transactions, McCreary directly owns 7,524 shares of NHC common stock.
- McCreary also holds options to purchase shares of common stock at prices of $63.96, $53.94, $94.10 and $90.62.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider transactions. It doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of restricted stock and stock options to a senior executive aligns their interests with the long-term performance of the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Stock option and restricted stock grants are a common form of compensation for executives in the healthcare industry, aligning their interests with shareholder value.
- The vesting schedules and exercise prices are typical for such grants.
Stakeholder Impact
- The grant of equity to executives can incentivize them to improve company performance, which benefits shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/18/2023 | Date of exercisable options to purchase common stock at $63.96, expiring 02/18/2027 |
| 03/08/2024 | Date of exercisable options to purchase common stock at $53.94, expiring 03/08/2028 |
| 01/01/2026 | First vesting date (33 1/3%) for the restricted shares granted on 03/05/2025 |
| 02/24/2026 | Date of exercisable options to purchase common stock at $90.62, expiring 02/24/2030 |
| 01/01/2027 | Second vesting date (33 1/3%) for the restricted shares granted on 03/05/2025 |
| 01/01/2028 | Final vesting date (33 1/3%) for the restricted shares granted on 03/05/2025 |
| 03/05/2029 | Expiration date for options to purchase common stock at $94.10 |
| 02/24/2030 | Expiration date for options to purchase common stock at $90.62 |
| 03/05/2025 | Date of transaction: Grant of restricted shares and stock options |
| 03/06/2025 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.